|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SCN7A |
Gene summary for SCN7A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SCN7A | Gene ID | 6332 |
| Gene name | sodium voltage-gated channel alpha subunit 7 | |
| Gene Alias | NaG | |
| Cytomap | 2q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0001508 | UniProtAcc | Q01118 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6332 | SCN7A | P8T-E | Human | Esophagus | ESCC | 2.12e-03 | 2.57e-01 | 0.0889 |
| 6332 | SCN7A | P9T-E | Human | Esophagus | ESCC | 8.38e-03 | 1.36e-01 | 0.1131 |
| 6332 | SCN7A | P11T-E | Human | Esophagus | ESCC | 3.66e-11 | 8.26e-01 | 0.1426 |
| 6332 | SCN7A | P19T-E | Human | Esophagus | ESCC | 2.95e-08 | 1.09e+00 | 0.1662 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SCN7A | SNV | Missense_Mutation | rs766963704 | c.4073N>A | p.Arg1358His | p.R1358H | Q01118 | protein_coding | deleterious(0.02) | benign(0.027) | TCGA-A1-A0SG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |
| SCN7A | SNV | Missense_Mutation | c.800G>A | p.Cys267Tyr | p.C267Y | Q01118 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
| SCN7A | SNV | Missense_Mutation | rs531498308 | c.1322N>T | p.Arg441Met | p.R441M | Q01118 | protein_coding | deleterious(0) | possibly_damaging(0.733) | TCGA-A8-A081-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SCN7A | SNV | Missense_Mutation | novel | c.560T>G | p.Val187Gly | p.V187G | Q01118 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-A8-A083-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SCN7A | SNV | Missense_Mutation | c.3403N>G | p.Leu1135Val | p.L1135V | Q01118 | protein_coding | deleterious(0) | possibly_damaging(0.487) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SCN7A | SNV | Missense_Mutation | c.1787N>C | p.Arg596Pro | p.R596P | Q01118 | protein_coding | deleterious(0.01) | benign(0.233) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SCN7A | SNV | Missense_Mutation | c.4948G>T | p.Asp1650Tyr | p.D1650Y | Q01118 | protein_coding | tolerated(1) | possibly_damaging(0.819) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SCN7A | SNV | Missense_Mutation | c.1815N>T | p.Lys605Asn | p.K605N | Q01118 | protein_coding | deleterious(0) | possibly_damaging(0.875) | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| SCN7A | SNV | Missense_Mutation | novel | c.3223A>T | p.Met1075Leu | p.M1075L | Q01118 | protein_coding | tolerated(0.23) | benign(0) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| SCN7A | SNV | Missense_Mutation | novel | c.442N>C | p.Glu148Gln | p.E148Q | Q01118 | protein_coding | tolerated(0.14) | benign(0.005) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6332 | SCN7A | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL856 | PRIMIDONE | |
| 6332 | SCN7A | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL1200440 | MEPIVACAINE HYDROCHLORIDE | |
| 6332 | SCN7A | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL16 | PHENYTOIN | |
| 6332 | SCN7A | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL1201020 | DISOPYRAMIDE PHOSPHATE | |
| 6332 | SCN7A | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL1200464 | PROPARACAINE HYDROCHLORIDE | |
| 6332 | SCN7A | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL1255654 | TETRACAINE HYDROCHLORIDE | |
| 6332 | SCN7A | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL1200334 | MORICIZINE HYDROCHLORIDE | |
| 6332 | SCN7A | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL1889140 | ROPIVACAINE HYDROCHLORIDE | |
| 6332 | SCN7A | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL87992 | ESLICARBAZEPINE ACETATE | |
| 6332 | SCN7A | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL944 | CHLOROPROCAINE HYDROCHLORIDE |
| Page: 1 2 3 4 5 6 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |